Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Oct 27;324(16):1620-1628.
doi: 10.1001/jama.2020.16195.

Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial

Miguel Valderrábano  1 , Leif E Peterson  1 , Vijay Swarup  2 , Paul A Schurmann  1   3 , Akash Makkar  2 , Rahul N Doshi  4 , David DeLurgio  5 , Charles A Athill  6 , Kenneth A Ellenbogen  7 , Andrea Natale  8 , Jayanthi Koneru  7 , Amish S Dave  1 , Irakli Giorgberidze  3 , Hamid Afshar  3 , Michelle L Guthrie  1 , Raquel Bunge  1 , Carlos A Morillo  9 , Neal S Kleiman  1
Affiliations
Randomized Controlled Trial

Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial

Miguel Valderrábano et al. JAMA. .

Abstract

Importance: Catheter ablation of persistent atrial fibrillation (AF) has limited success. Procedural strategies beyond pulmonary vein isolation have failed to consistently improve results. The vein of Marshall contains innervation and AF triggers that can be ablated by retrograde ethanol infusion.

Objective: To determine whether vein of Marshall ethanol infusion could improve ablation results in persistent AF when added to catheter ablation.

Design, setting, and participants: The Vein of Marshall Ethanol for Untreated Persistent AF (VENUS) trial was an investigator-initiated, National Institutes of Health-funded, randomized, single-blinded trial conducted in 12 centers in the United States. Patients (N = 350) with persistent AF referred for first ablation were enrolled from October 2013 through June 2018. Follow-up concluded in June 2019.

Interventions: Patients were randomly assigned to catheter ablation alone (n = 158) or catheter ablation combined with vein of Marshall ethanol infusion (n = 185) in a 1:1.15 ratio to accommodate for 15% technical vein of Marshall ethanol infusion failures.

Main outcomes and measures: The primary outcome was freedom from AF or atrial tachycardia for longer than 30 seconds after a single procedure, without antiarrhythmic drugs, at both 6 and 12 months. Outcome assessment was blinded to randomization treatment. There were 12 secondary outcomes, including AF burden, freedom from AF after multiple procedures, perimitral block, and others.

Results: Of the 343 randomized patients (mean [SD] age, 66.5 [9.7] years; 261 men), 316 (92.1%) completed the trial. Vein of Marshall ethanol was successfully delivered in 155 of 185 patients. At 6 and 12 months, the proportion of patients with freedom from AF/atrial tachycardia after a single procedure was 49.2% (91/185) in the catheter ablation combined with vein of Marshall ethanol infusion group compared with 38% (60/158) in the catheter ablation alone group (difference, 11.2% [95% CI, 0.8%-21.7%]; P = .04). Of the 12 secondary outcomes, 9 were not significantly different, but AF burden (zero burden in 78.3% vs 67.9%; difference, 10.4% [95% CI, 2.9%-17.9%]; P = .01), freedom from AF after multiple procedures (65.2% vs 53.8%; difference, 11.4% [95% CI, 0.6%-22.2%]; P = .04), and success achieving perimitral block (80.6% vs 51.3%; difference, 29.3% [95% CI, 19.3%-39.3%]; P < .001) were significantly improved in vein of Marshall-treated patients. Adverse events were similar between groups.

Conclusions and relevance: Among patients with persistent AF, addition of vein of Marshall ethanol infusion to catheter ablation, compared with catheter ablation alone, increased the likelihood of remaining free of AF or atrial tachycardia at 6 and 12 months. Further research is needed to assess longer-term efficacy.

Trial registration: ClinicalTrials.gov Identifier: NCT01898221.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Valderrábano reported serving as a consultant for Biosense Webster; a speaker for Boston Scientific; research support member for Circa Scientific; and consultant and speaker for Baylis Medical. Dr Swarup reported providing research and consulting services to Biosense Webster, Boston Scientific, and Abbott outside the submitted work. Dr Athill reported receiving grants and other funding from Methodist Hospital Research Institute during the conduct of the study and grants and personal fees from Boston Scientific and Abbott Laboratories; grants from Biosense Webster; and personal fees from Janssen Pharmaceutical and Zoll Medical outside the submitted work. Dr Natale reported receiving personal fees from Biosense Webster, Biotronik, Medtronic, Boston Scientific, and Abbott during the conduct of the study and outside the submitted work. Dr Dave reported serving as a consultant to Abbott outside the submitted work. Dr Bunge reported receiving grants from Houston Methodist Research Institute during the conduct of the study. Dr Morillo reported receiving personal fees from Medtronic and serving as a member of the steering committee of the STAR AF trials for Abbott outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Clinical Trial Conduct
aSites were not required to provide screening logs during the recruitment phase. Thus, the number of patients assessed for eligibility is not available.
Figure 2.
Figure 2.. Time to Recurrence of Atrial Fibrillation or Tachycardia and Atrial Fibrillation Burden
The figure shows time to recurrence of atrial fibrillation or tachycardia in the as-randomized (A) and as-treated (B) analyses and atrial fibrillation burden (C), quantified as percentage of atrial fibrillation or tachycardia over 1-month monitoring at 6 and 12 months of follow-up. Boxes represent interquartile ranges (zero for vein of Marshall ethanol plus catheter ablation groups). Whiskers represent maximum values (third quartile plus 1.5 times interquartile range − zero for vein of Marshall ethanol plus catheter ablation groups). Dots represent outliers.
See this image and copyright information in PMC

References

    1. Calkins H, Hindricks G, Cappato R, et al. . 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444. doi:10.1016/j.hrthm.2017.05.012 - DOI - PMC - PubMed
    1. Haïssaguerre M, Jaïs P, Shah DC, et al. . Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666. doi:10.1056/NEJM199809033391003 - DOI - PubMed
    1. Dixit S, Marchlinski FE, Lin D, et al. . Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm Electrophysiol. 2012;5(2):287-294. doi:10.1161/CIRCEP.111.966226 - DOI - PubMed
    1. Verma A, Jiang CY, Betts TR, et al. ; STAR AF II Investigators . Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812-1822. doi:10.1056/NEJMoa1408288 - DOI - PubMed
    1. Lee SH, Tai CT, Hsieh MH, et al. . Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation. J Am Coll Cardiol. 2005;46(6):1054-1059. doi:10.1016/j.jacc.2005.06.016 - DOI - PubMed

Publication types

Associated data